American patients would ultimately bear the cost of President Donald Trump‘s threatened tariffs on generic drugs, the CEO of Swiss pharmaceutical company Sandoz told CNBC, warning that manufacturers could be forced to raise prices or stop supplying some medicines. “Patients pay the tariff,” Sandoz CEO Richard Saynor said in an interview with CNBC during its…
U.S. President Donald Trump delivers remarks on his administration’s healthcare policies, in the Oval Office at the White House in Washington, D.C., U.S., Aug. 31, 2026. Evelyn Hockstein | Reuters President Donald Trump on Monday said he struck new drug pricing deals with nine drugmakers to voluntarily sell their medications for less, building on his…
We’re selling 10 shares of Eli Lilly at roughly $1,269 each. Following Wednesday’s trade, Jim Cramer’s Charitable Trust will own 80 shares of LLY, decreasing its weighting in the portfolio to 2.6% from 2.9%. We’re locking in big gains in pharma giant Eli Lilly as shares jump to a fresh record high on Wednesday. Healthcare…
Eli Lilly has won its first approval to sell its weight-loss drug Foundayo outside the U.S., allowing it to compete with rival Novo Nordisk’s Wegovy pill in the U.K. It marks only the second GLP-1 weight-loss pill in the European market and comes just two months after Novo launched its Wegovy pill there. The U.K.’s…
Inflation data for July takes center stage in the week ahead, as second-quarter earnings season winds down. Another factor that could influence the market action: updates on the Iran war. Though Treasury Secretary Scott Bessent said early last week that a deal may be coming , that news never materialized. That’s not to say a…
AI stocks came roaring back this week as investors worked through another wave of corporate earnings and a surprisingly weak July jobs report . The major averages notched a second straight week of gains, with the Dow Jones Industrial Average and S & P 500 both touching record highs. The blue-chip index closed at a…
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters The diverging paths of two GLP-1 drugmakers were on full display this week. Both Eli Lilly and Novo Nordisk beat second-quarter estimates and raised their full-year outlooks. But while investors cheered Lilly’s results, sending shares higher on Wednesday, they punished Novo…
Novo Nordisk’s quarterly beat and guidance increase did little to resolve Wall Street’s biggest concern: whether the Ozempic maker has a convincing path back to sustainable growth as competition from Eli Lilly intensifies. Analysts said the better-than-expected quarter benefited from rebate adjustments and other temporary factors, obesity drug sales were broadly in line with expectations,…
The jobs market steps into the spotlight this week, while second-quarter earnings season continues apace. Here’s a closer look at what to expect in the coming days. We’ll start with the Club holdings set to report, before touching on the labor-market updates and their implications for Federal Reserve policy. 1. Earnings : The action kicks…
Wall Street got back to its winning ways last week after navigating a hawkish Federal Reserve meeting, volatile swings in chip stocks, and a critical round of Big Tech earnings. The Dow Jones Industrial Average rose 1% for the week, snapping a three-week losing streak. The S & P 500 gained 1% last week, while…
